All News
Filter News
Found 163 articles
-
Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update
10/18/2022
Recce Pharmaceuticals Ltd is pleased to provide an update from its preclinical studies evaluating RECCE® 327 (R327) against the SARS-CoV-2 virus.
-
Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs
10/3/2022
Recce Pharmaceuticals Ltd, the Company developing new classes of synthetic anti-infectives, is pleased to provide an updated timeline on its clinical programs with several significant data read-outs in 2022 and 2023.
-
Recce Pharmaceuticals Appoints Alistair McKeough to its Board of Directors
9/7/2022
Recce Pharmaceuticals Ltd is pleased to announce the appointment of Alistair McKeough to its Board of Directors.
-
Russian researchers announced a new Sputnik V vaccine against the Delta and Omicron variants of COVID-19, AB Science files for conditional marketing approval of its ALS drug in the EU and much more.
-
Recce Pharmaceuticals Announces Positive Safety Data from Seventh Cohort of Phase 1 Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
8/23/2022
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the company developing a new class of synthetic anti-infectives, is pleased to report that in cohort seven of a Phase 1 clinical trial, RECCE® 327 (R327) intravenously dosed at 6,000mg (a 120-fold increase from cohort one at 50mg) over a 1-hour infusion demonstrated no serious adverse effects among 10 healthy male subjects.
-
New leaders and top executive roles were selected to guide biopharma and life science companies from Apertura Gene Therapy to CytoDyn, Vaccentis AG, Suvoda LLC, IN8bio and more.
-
Recce Pharmaceuticals Appoints Philip Sutton, Ph.D., as Vice President of Translational Sciences
7/12/2022
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the company developing a new class of synthetic anti-infectives, is pleased to announce the appointment of Philip Sutton, Ph.D., as Vice President of Translational Sciences.
-
Olink said the measurement of proteins at "population scale" provides the ability to improve the understanding of underlying mechanisms of diseases.
-
Recce Pharmaceuticals Announces Positive Safety Data from Sixth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
6/22/2022
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the company developing a new class of synthetic anti-infectives, is pleased to report that in cohort six of a Phase I clinical trial, RECCE® 327 (R327) demonstrated a good safety and tolerability profile among 10 healthy male subjects intravenously dosed at 4,000mg (an 80-fold increase from cohort one at 50mg).
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Recce Pharmaceuticals Announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE® 327 and Initiates Sixth Cohort at 4,000mg
5/23/2022
Recce Pharmaceuticals Ltd. (ASX:RCE, FSE:R9Q) (the Company), the company developing a new class of synthetic anti-infectives, today announced that in cohort five of a Phase I clinical trial, R327 demonstrated a good safety and tolerability profile among 10 healthy male subjects intravenously dosed at 2,000mg.
-
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
-
Recce Pharmaceuticals Announces Phase I Clinical Trial of RECCE® 327 Advances to High Dosing Level
4/13/2022
Recce Pharmaceuticals Ltd. (ASX:RCE, FSE:R9Q) (the Company), the company developing a new class of synthetic anti-infectives, is pleased to report an Independent Safety Committee data review of 10 healthy human subjects dosed in a Phase I intravenous (IV) clinical trial of RECCE® 327 (R327), demonstrating good safety and tolerability at 1,000mg.
-
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
4/12/2022
Recce Pharmaceuticals Limited is pleased to announce the Intellectual Property Department of the Hong Kong Special Administrative Region has granted patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection,” furthering marketing and manufacturing exclusivity to February 2037.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Recce Pharmaceuticals Announces Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
3/30/2022
Recce Pharmaceuticals Ltd is pleased to report Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) cohort four at 1,000mg (twenty-fold increase on cohort one 50mg dose), indicating a good safety and tolerability profile among 10 healthy male subjects.
-
Recce Pharmaceuticals Receives Research and Development (R&D) Incentive Rebate
3/29/2022
Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, is pleased to announce it has received a Research and Development Tax Incentive rebate of A$3,084,955.19 from the Australian Tax Office for the year ending June 30, 2021.
-
Recce Pharmaceuticals Announces Safety Committee Clears Next Dose in Phase I Study of RECCE® 327
3/8/2022
Recce Pharmaceuticals Ltd is pleased to report an Independent Safety Committee data review of 10 healthy human subjects intravenously dosed in the Phase I intravenous clinical trial of RECCE® 327, demonstrating a good safety and tolerability profile – unanimously recommending cohort four to commence.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.